Step aside, Orkambi. Vertex’s new-and-improved cystic fibrosis combo Symdeko is here, and it comes with a boost to Vertex's sales. Upshot? The CF-focused biotech is on track to hit its $2.84 billion forecast from the franchise this year.Original Article
FDA nod for Vertex’s improved CF combo, Symdeko, opens $200M door this year
